MD - Internal Medicine - All India Institute Of Medical Sciences - New Delhi Verified
DM - Medical Oncology - All India Institute Of Medical Sciences - New Delhi Verified
Experiences
Senior Resident - Department of Medical Oncology AIIMS - New Delhi
Resident Super Specialist MNJ Institute of Oncology and Regional Cancer Center - Hyderabad
Consultant Medical Oncology Krishna Institute of Medical Sciences
Consultant Medical Oncologist American Oncology Institute - Hyderabad
Consultant Medical Oncologist Star Hospitals - Nanakramguda - Currently Working
Awards and Recognitions
“Abstract Achievement Award” at American Society of Hematology Meeting on Hematological Malignancies held in Chicago for the abstract “Prognostic Significance of Neutrophil-Lymphocyte Ratio in Advanced Pediatric Hodgkin Lymphoma-A Multicentric Analysis of 186 patients”- 2016
Received Scholarship for Oral presentation in SIOP-2015- Cape Town- South Africa for the abstract “Outcome Of Pediatric Hodgkin Lymphoma Treated With ABVD: A Multicentric Analysis Of 335 Patients”
Won Sorel Catherine Prize for Best Post Graduate in Pediatrics for the Year 2012
Stood 2nd in NNF Gold Medal Paper for the Year 2012(1)
Paper Presentations
Bhethanabhotla S, Bakhshi S. Reply: Neither Post-Treatment PET-CT Nor Interim PET-CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma. J Nucl Med. 2016 Dec8;IMPACT FACTOR: 7.439
Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, Et Al. Outcome Of Pediatric Advanced Hodgkin Lymphoma Treated with ABVD and Predictors of Inferior Survival: A Multicenter Study of 186 Patients. Leuk Lymphoma. 2016 Dec 6;1–7. IMPACT FACTOR:2.644
Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, Et Al. Post- Treatment PET-CT Rather Than Interim PET-CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET-CT Versus Conventional Imaging. J Nucl Med. 2016 Oct 6; IMPACT FACTOR: 7.439
Bhethanabhotla S, Bakhshi S. Presence of Risk Factors Does Not Affect Outcome in Early Stage Pediatric Hodgkin Lymphoma Treated with ABVD. Ann Hematol. 2016 Nov 18; IMPACT FACTOR: 2.845
Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports. Nucl Med Mol Imaging. 2016 Sep;50(3):261–5.
Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, Et Al. Primary Diffuse Large B-Cell Lymphoma of the Prostate: A Report of Two Cases with Diagnostic Considerations. J Cancer Res Ther. 2015 Dec;11(4):977–9. IMPACT FACTOR: 0.8459
Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, Et Al. Synchronous Metastatic Pulmonary Adenocarcinoma with Small Cell Lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678–80. IMPACT FACTOR: 2.644
Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of Position of Infant During Phototherapy in Management of Hyperbilirubinemia in Late Preterm and Term Neonates: A Randomized Controlled Trial. J Perinatol. 2013 Oct;33(10):795–9. IMPACT FACTOR: 2.183
Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, Et Al. Autologous Stem Cell Transplantation for Multiple Myeloma: Long-Term Results. The National Medical Journal of India. 2016 Jul 1;29(4):192. IMPACT FACTOR: 0.786
Bhethanabhotla, S., Tiwari, A., Sharma, M.C. Et Al. Prognostic Significance of IL-6 In Hodgkin Lymphoma. Indian J Pediatr. 2019 Mar 4;Online First. IMPACT FACTOR: 1.046
Patel A, Tannock I, Bhethanabhola S, Srivastva P, Biswas B, Et Al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is it Practice Changing Facts and Facets.JCO Glob Oncol. 2020 Mar;6:382-386. IMPACT FACTOR:1.79